CD8+ T cells in the cancer-immunity cycle
Immunity · 2023-10 · 56 (10) · 2231-2253
DOI: 10.1016/j.immuni.2023.09.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunity, 2023-10. Verfasst von Josephine R Giles und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology and Im…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 516-mal zitiert (Crossref) und nennt 301 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIA NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer immunotherapy involve CD8+ T cell effector function. Here, we review the current understanding of T cell function in cancer, focusing on key CD8+ T cell subtypes and states. We discuss factors that influence CD8+ T cell differentiation and function in cancer through a framework that incorporates the classic three-signal model and a fourth signal-metabolism-and also consider the impact of the tumor microenvironment from a T cell perspective. We argue for the notion of immunotherapies as "pro-drugs" that act to augment or modulate T cells, which ultimately serve as the drug in vivo, and for the importance of overall immune health in cancer treatment and prevention. The progress in understanding T cell function in cancer has and will continue to improve harnessing of the immune system across broader tumor types to benefit more patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania,…
- NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
- NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA 92037, USA. Electronic address: skaech@salk.edu.
Förderung
- NCI NIH HHS
- NIA NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
- Parker Institute for Cancer Immunotherapy
- NIH
- NOMIS Foundation
- Pfizer
Zitieren
APA
Giles, J. R., Globig, A. M., Kaech, S. M., & Wherry, E. J. (2023). CD8+ T cells in the cancer-immunity cycle. Immunity, 56(10), 2231-2253. https://doi.org/10.1016/j.immuni.2023.09.005
Vancouver
Giles JR, Globig AM, Kaech SM, Wherry EJ. CD8+ T cells in the cancer-immunity cycle. Immunity. 2023;56(10):2231-2253. doi:10.1016/j.immuni.2023.09.005
BibTeX
@article{Giles2023,
author = {Giles, Josephine R and Globig, Anna-Maria and Kaech, Susan M and Wherry, E John},
title = {CD8+ T cells in the cancer-immunity cycle},
journal = {Immunity},
year = {2023},
volume = {56},
number = {10},
pages = {2231--2253},
doi = {10.1016/j.immuni.2023.09.005}
}
EUVIMED